- Home
- MRK vs SCLXW Comparison
MRK vs SCLXW Comparison
Compare MRK & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRK
- SCLXW
- Stock Information
- Founded
- MRK 2000
- SCLXW N/A
- Country
- MRK United States
- SCLXW United States
- Employees
- MRK N/A
- SCLXW 111
- Industry
- MRK Biotechnology: Pharmaceutical Preparations
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- MRK Health Care
- SCLXW Health Care
- Exchange
- MRK Nasdaq
- SCLXW Nasdaq
- Market Cap
- MRK 198.5B
- SCLXW N/A
- IPO Year
- MRK N/A
- SCLXW N/A
- Fundamental
- Price
- MRK $83.30
- SCLXW $0.10
- Analyst Decision
- MRK Buy
- SCLXW
- Analyst Count
- MRK 15
- SCLXW 0
- Target Price
- MRK $113.14
- SCLXW N/A
- AVG Volume (30 Days)
- MRK 18.0M
- SCLXW 4.0K
- Earning Date
- MRK 07-29-2025
- SCLXW 03-07-2025
- Dividend Yield
- MRK 3.89%
- SCLXW N/A
- EPS Growth
- MRK 667.14
- SCLXW N/A
- EPS
- MRK 6.88
- SCLXW N/A
- Revenue
- MRK $63,922,000,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- MRK $2.42
- SCLXW N/A
- Revenue Next Year
- MRK $5.77
- SCLXW N/A
- P/E Ratio
- MRK $12.12
- SCLXW N/A
- Revenue Growth
- MRK 4.10
- SCLXW 22.02
- 52 Week Low
- MRK $73.31
- SCLXW $0.18
- 52 Week High
- MRK $129.93
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- MRK 60.59
- SCLXW N/A
- Support Level
- MRK $80.15
- SCLXW N/A
- Resistance Level
- MRK $85.00
- SCLXW N/A
- Average True Range (ATR)
- MRK 1.84
- SCLXW 0.00
- MACD
- MRK 0.37
- SCLXW 0.00
- Stochastic Oscillator
- MRK 75.22
- SCLXW 0.00
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.